GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Myos Rens Technology Inc (NAS:MYOS) » Definitions » Price-to-Free-Cash-Flow

Myos Rens Technology (Myos Rens Technology) Price-to-Free-Cash-Flow : N/A (As of May. 05, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Myos Rens Technology Price-to-Free-Cash-Flow?

As of today (2024-05-05), Myos Rens Technology's share price is $12.12. Myos Rens Technology's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2020 was $-3.08. Hence, Myos Rens Technology's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Myos Rens Technology's Price-to-Free-Cash-Flow or its related term are showing as below:

MYOS's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.61
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Myos Rens Technology's Free Cash Flow per Share for the three months ended in Sep. 2020 was $-0.55. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-3.08.


Myos Rens Technology Price-to-Free-Cash-Flow Historical Data

The historical data trend for Myos Rens Technology's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myos Rens Technology Price-to-Free-Cash-Flow Chart

Myos Rens Technology Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Myos Rens Technology Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Myos Rens Technology's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Myos Rens Technology's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myos Rens Technology's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Myos Rens Technology's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Myos Rens Technology's Price-to-Free-Cash-Flow falls into.



Myos Rens Technology Price-to-Free-Cash-Flow Calculation

Myos Rens Technology's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=12.12/-3.081
=N/A

Myos Rens Technology's Share Price of today is $12.12.
Myos Rens Technology's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.08.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Myos Rens Technology  (NAS:MYOS) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Myos Rens Technology Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Myos Rens Technology's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Myos Rens Technology (Myos Rens Technology) Business Description

Traded in Other Exchanges
N/A
Address
45 Horsehill Road, Suite 106, Cedar Knolls, NJ, USA, 07927
Myos Rens Technology Inc is a US-based bio-nutrition and biotherapeutics company. It focuses on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. The company develops nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases such as Sarcopenia, Cachexia, and others.
Executives
Joseph Mannello director, officer: Chief Executive Officer C/O BREAN CAPITAL, LLC, 1345 AVENUE OF THE AMERICAS, 29TH FLOOR, NEW YORK NY 10105
Victor E Mandel director PO BOX 5962, WASHINGTON DC 20016
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Christopher Pechock director C/O MATLINPATTERSON GLOBAL ADVISORS INC, 520 MADISON AVE, NEW YORK NY 10022-4213
Christopher C Dewey director 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Louis J. Aronne director 4640 ADMIRALTY, SUITE 500, MARINA DEL RAY CA 90292
Eric Zaltas director 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ 07927
Andrew Joel Ponte director 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
David J Matlin 10 percent owner
John Nosta director 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Zhengguang Lyu director 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Ren Ren director, 10 percent owner 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Rens Technology Inc 10 percent owner 150 DRAKE STREET ROOM 7F, POMONA CA 91767
Rens Agriculture Science & Technology Co, Ltd 10 percent owner 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Guiying Zhao director 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019